Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Aug 14;2005(3):175-9.
doi: 10.1155/MI.2005.175.

Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction

Affiliations

Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction

A Arakelyan et al. Mediators Inflamm. .

Abstract

Chemokine-driven migration of inflammatory cells has been implicated in pathogenesis of atherosclerosis-associated conditions such as ischemic stroke and myocardial infarction. In this study, a candidate chemokine, monocyte chemoattractant protein (MCP)-1, was investigated in patients with both aforementioned manifestations of atheroslerotic inflammation. MCP-1 levels in serum were determined by ELISA in 40 healthy, control subjects (C), 40 patients with ischemic stroke (IS), and in 64 patients with myocardial infarction (MI). Statistical analysis utilised Mann-Whitney test, Fisher's exact test, and Spearman's rank correlation (P < .05). In comparison to control subjects (C; median/interquartile range: 239/126 pg/mL), MCP-1 serum levels were increased in both investigated patient cohorts (IS: 384/370, P < .001; MI: 360/200, P < .002). There was a substantial variability of MCP-1 serum levels, especially in the IS group. No relationship was observed between chemokine levels and atherosclerosis risk factors (hypertension, diabetes, smoking, and alcohol consumption), and MCP-1 was also not related to age or gender. Elevation of MCP-1 in circulation of patients with atherosclerosis-associated complications implicates this CC chemokine ligand (CCL)2 in inflammatory processes, which contribute to pathogenesis of myocardial infarction and ischemic stroke. Further investigations, including patient stratification, are however necessary to evaluate if MCP-1 can be utilised for clinical management of patients with these diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Monocyte chemoattractant protein (MCP)-1 levels (pg/mL) in serum of patients with myocardial infarction (MI, n = 64), ischemic stroke (IS, n = 40), and healthy, control subjects (n = 40). The data are expressed as whisker box plots; the box represents the 25–75th percentiles, the median is indicated by a bar across the box, the whiskers on each box represent the 10–90th percentiles. P < .002 when comparing with the control group.

Similar articles

Cited by

References

    1. Pockley AG. Heat shock proteins, inflammation, and cardiovascular disease. Circulation. 2002;105(8):1012–1017. - PubMed
    1. Warlow CP. Epidemiology of stroke. Lancet. 1998;352(suppl 3):SIII1–SIII4. - PubMed
    1. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64(1):5–15. - PubMed
    1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–126. - PubMed
    1. Liuzzo G. Atherosclerosis: an inflammatory disease. Rays. 2001;26(4):221–230. - PubMed

Publication types